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ABSTRACT 
 
INVESTIGATION OF THE 4-AMINO-α,α-DIHYDROXY-3,5-DICHLOROACETOPHENONE IMPURITY 
IN THE SYNTHESIS OF CLENBUTEROL HYDROCHLORIDE 
By Kerry Elizabeth Moore 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Chemistry at Virginia Commonwealth University. 
Virginia Commonwealth University, 2014 
Advisor:  Dr. Scott Gronert, Department Chair and Professor, Chemistry 
 
Clenbuterol Hydrochloride is a bronchodilator marketed as Spirospent® for Human 
Pharmaceuticals and as Ventipulmin® for Veterinary Pharmaceuticals by Boehringer Ingelheim.1   This 
research investigates formation of the 4-amino-α,α-dihydroxy-3,5-dichloroacetophenone impurity 
(Dihydroxy Impurity) in the synthesis of Clenbuterol Hydrochloride.   The Dihydroxy Impurity has 
increased three-fold since the process was transferred to Boehringer Ingelheim Chemicals, Inc. in 1999.1   
The Dihydroxy Impurity is proposed to be produced during an amination/reduction step from a 
reaction of water with the starting material.9  Additionally, the Dihydroxy Impurity can be formed by the 
reaction of water with an impurity,  4-amino-α,α-didibromo-3,5-dichloroacetophenone (dibromo 
impurity), that is generated in the previous step.9 
The formation of the dibromo impurity was investigated through a series of Design of 
Experiments (DoE) analyses.  The results from these analyses, presented within, determined the 
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optimum bromination conditions to reduce the dibromo impurity.  These conditions were able to reduce 
the dibromo impurity by 75%. 
A series of water spiking experiments with both the starting material of the amination/reduction 
step and the dibromo impurity were performed to investigate the formation of the Dihydroxy Impurity.  
Based on the results, a mechanism for the formation of the Dihydroxy Impurity is presented.  The three-
fold increase of the Dihydroxy Impurity was concluded to be due to ≥ 15% water in the 
amination reaction mixture reacting with the starting material.   
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INTRODUCTION 
 
Clenbuterol Hydrochloride 
Clenbuterol Hydrochloride 1 (Figure 1), 4-amino-α-[(tert-butylamino)methyl]-3,5-
dichlorobenzyl alcohol hydrochloride, is used as a decongestant and bronchodilator to treat 
breathing disorders, such as asthma.1   
Figure 1:  Clenbuterol Hydrochloride 
NH2
ClCl
HO
N
H
HCl
1  
Clenbuterol Hydrochloride 1 was first synthesized at Thomae, a Boehringer Ingelheim research 
facility in Biberach, Germany, in 1967.1  The synthesis of Clenbuterol Hydrochloride 1 was 
patented in the United States in 1970.2  After comprehensive clinical trials, Clenbuterol 
Hydrochloride 1 was approved for the treatment of reversible airway obstruction in Germany 
in 1976 and later as a veterinary pharmaceutical for the treatment of bronchiolytic disorders in 
Germany in 1980.1  Boehringer Ingelheim markets Clenbuterol Hydrochloride 1 as Spirospent® 
for Human Pharmaceuticals and as Ventipulmin® for Veterinary Pharmaceuticals.1  Clenbuterol 
Hydrochloride 1 is not approved by the Federal Drug Administration for human use in the 
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United States, and the Clenbuterol Hydrochloride 1 currently made at Boehringer Ingelheim 
Chemicals, Inc. (BICI), in Petersburg, Virginia,  primarily goes to Veterinary Pharmaceuticals.1 
 
Overview of Clenbuterol Hydrochloride Process at BICI 
The Clenbuterol Hydrochloride 1 process, shown in Scheme 1, was transferred from 
Thomae, in Biberach, Germany, to Boehringer Ingelheim Chemicals, Inc., in Petersburg, 
Virginia, in 1999. 1   Scheme 1 shows the 2013 average yields for each step. 
Scheme 1: Clenbuterol Hydrochloride Process 
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The first step of the process (Scheme 1, 23P) involves the double chlorination of 4-
aminoacetaphenone 2 through an electrophilic aromatic substitution reaction to yield 4-amino-
3,5-dichloroacetophenone 3P (ADAP).1  The chlorination is followed by two purification steps:  a 
slurry in cyclohexane to remove 2,4,6-trichloroaniline resulting from over chlorination3 and a 
crystallization in ethyl acetate to remove the mono-chlorinated impurity, 4-amino-3-
chloroacetophenone.1 ADAP 3P is analyzed by HPLC to ensure the removal these impurities.4   
ADAP 3P is brominated alpha to the ketone and purified twice (Scheme 1, 3P4P) to 
yield 4-amino-α-bromo-3,5-dichloroacetophenone 4P.  The purpose of the purification steps 
was not described in the documentation associated with the transfer of the process.  
Additionally, neither of the intermediates, 4 nor 4P, are analyzed for purity.  Therefore, the 
purpose of the two purification steps and the purity of the product 4P going into the next step 
are not fully clear.   
In the third step of the process, the bromide of 4P is displaced by tert-butylamine 
followed by reduction of the ketone moiety of 4P with sodium borohydride (NaBH4) to yield 
Clenbuterol Crude Free Base 5 (Scheme 1, 4P5P), which is crystallized twice in ethanol in 
order to remove the 4-amino-α,α-dihydroxy-3,5-dichloroacetophenone (dihydroxy impurity).1  
The formation of the dihydroxy impurity is discussed in more detail in the next section.  The 
Clenbuterol Free Base 5P intermediate is analyzed by HPLC to ensure the removal of the 
dihydroxy impurity before the material is processed further.5 
The Clenbuterol Free Base 5P is treated with hydrochloric acid in isopropanol to yield 
the hydrochloride salt, which is dried followed by the product being sieved to yield the final 
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product, Clenbuterol Hydrochloride 1 (Scheme 1, 5P1).  The final product is analyzed as per 
the specifications shown in Table 1.6    
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Table 1: Clenbuterol Hydrochloride Specifications6 
Test Acceptance Criterion 
Description White to yellowish powder or crystalline substance 
Identification 
IR Compares to standard spectrum 
Test for Chlorides Positive for Chlorides 
Solubility Soluble in water and ethanol, sparingly in acetone 
Appearance 
of Solution 
Clarity Not more opalescent than reference II 
Color Not more intensely colored than reference Y6 
pH 5.0 – 6.5 
Optical Rotation -0.10° to +0.10° 
Residue on Ignition ≤ 0.1% 
Heavy Metals ≤ 10 ppm 
Water Content ≤ 0.5% 
Titration Assay 99.0 – 101.0% 
HPLC Assay 98.0 – 102.0% 
HPLC 
Impurities 
Individual (known) ≤ 0.1% 
Individual (unknown) ≤ 0.10% 
Total ≤ 0.2% 
Residual 
Solvents 
Cyclohexane ≤ 0.300% 
Ethanol ≤ 0.010% 
Ethyl Acetate ≤ 0.500% 
Isopropanol ≤ 0.300% 
Toluene ≤ 0.005% 
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History of the Dihydroxy Impurity 
 Dihydroxy impurity 7 (Figure 2) is observed during the testing of the Clenbuterol Free 
Base 5P intermediate.   
Figure 2:  Dihydroxy Impurity 
 
When the process was transferred to Petersburg, VA, the Clenbuterol Crude Free Base 
intermediate 5 contained an average of 1.0 % of dihydroxy impurity 7; however, during 
campaigns from 2007 to 2008, the Clenbuterol Crude Free Base intermediate 5 contained over 
three times that amount of dihydroxy impurity 7, an average of 3.4% (Figure 3).7   
Figure 3:  Increase in Dihydroxy Impurity 
 
As a result of the three-fold increase of dihydroxy impurity 7, a second crystallization was 
added in 2012 in order to get consistent quality and ensure that the Clenbuterol Free Base 
intermediate 5P met specification.8 
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The proposed pathway for the formation of dihydroxy impurity 7 during the 
amination/reduction reaction (Scheme 1, 4P5P) is shown in Scheme 2 below:  the reaction of 
the bromination product 4P in a haloform-like reaction with hypobromic acid to form the 4-
amino-α,α-dibromo-3,5-dichloroacetophenone (dibromo impurity 9), which can then be 
hydrolyzed to the dihydroxy impurity 7.9   
Scheme 2:  Potential Routes to the Dihydroxy Impurity 
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Hypobromic acid is proposed to be formed from an hydroxide anion attacking the bromide of 
ADBAP 4P, as shown in the box at the bottom of Scheme 2.  Additionally, a precursor to the 
dihydroxy impurity 7, the dibromo impurity 9, may also be coming into the amination/reduction 
reaction (Scheme 1, 4P5P) as an impurity from the bromination reaction (Scheme 1, 
Reaction 3P4P).9   The carbonyl of dihydroxy impurity 7 is not reduced by sodium borohydride 
during the reduction reaction because it likely exists in the enol form under the reaction 
conditions. 
The bromination product 4 or 4P is not tested for purity and, therefore, it is not known 
how much of dibromo impurity 9 is generated in the bromination process and may be carried 
forward to make dihydroxy impurity 7.  Additionally, the water content going into the 
amination reaction (Scheme 1, 4P5, Step 1) is not characterized. 
 
Research Objective 
 Since the Clenbuterol HCl 1 process was transferred to Boehringer Ingelheim Chemicals, 
Inc., dihydroxy impurity 7 has increased by over three-fold in the amination/reduction reaction 
(Scheme 1, 4P5P).7  It is proposed  that dihydroxy impurity 7 is formed from a reaction of 
water  with either bromination product 4P or dibromo impurity 9 (Scheme 2).  The purpose of 
this work is to understand the formation of dihydroxy impurity 7 by investigating dibromo 
impurity 9 formed in the bromination reaction (Scheme 1, 3P4P) and the water content going 
into the amination/reduction step (Scheme 1, 4P5P).  
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Design of Experiments 
 In the investigation of the dibromo impurity 9, a statistical method of planning 
experiments and analyzing the data called Design of Experiments (DoE) was employed.  DoE has 
benefits over the classic method of changing one factor at a time, such as looking at the entire 
range of all factors (also known as the design space) and investigating at the interactions 
between factors.  A pictorial representation of how both the one factor at a time method and 
DoE work is shown below in Figure 4.   
 
Figure 4:  One Factor at Time vs. Design of Experiments 
 
In the method of changing one factor at a time, Factor 1 (for example temperature) is 
tested with experiments (yellow dots) at high and low ranges until an optimum temperature is 
found based on the predetermined outputs.  Factor 2 (for example concentration) is then 
tested at the optimum temperature and Factor 3 (for example equivalents of a reactant) is 
tested at the optimum temperature and concentration to determine the optimum conditions 
for the desired outputs; however, this method does not give any information about the 
interactions between the factors.  The factors could interact in a way that the optimum 
conditions may not be explored by the one factor at a time method, as can be seen by the 
missing quadrants (red quadrants in Figure 4) in the one factor at time model. 
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The DoE method inputs all of the factors initially and a series of experiments (yellow 
dots), testing the entire range of all factors, is generated in a random order typically using 
statistical software, such as Minitab©.  Randomization of the experiments averages out the 
experimental error and the variation due to extraneous factors that are not controlled.10 A full 
factorial DoE would run experiments with all variations of factors in their the defined range.  A 
half factorial DoE would run half the experiments of a full factorial DoE, and a quarter factorial 
DoE would run a quarter of the experiments of a full factorial DoE.  The lower factorial designs 
are useful to run a minimal number of experiments to determine what factors influence the 
output.  Additionally, experiments may also be run in duplicate to estimate the experimental 
error or chance of variability.  
11 
 
 
RESULTS AND DISCUSSIONS 
Chlorination 
 The first step of the Clenbuterol Hydrochloride 1 process (Scheme 3) is a double 
chlorination of 4-aminoacetaphenone 2 through an electrophilic aromatic substitution reaction 
and two purification steps to yield 4-amino-3,5-dichloroacetophenone 3P (ADAP).1 
Scheme 3:  Chlorination 
 
The double chlorination is followed by two purification steps:  a slurry in cyclohexane to remove 
2,4,6-trichloroaniline resulting from over chlorination3 and a crystallization in ethyl acetate to 
remove the mono-chlorinated impurity, 4-amino-3-chloroacetophenone.1   
 Due to the ortho/para directing, electron donating, amino group and the meta directing, 
electron withdrawing, acetyl group, chlorination of 4-aminoacetophenone occurs primarily at 
the 3 and 5 positions over the 2 and 4 positions.  Therefore, under chlorination would produce 
only the mono-chlorinated impurity, 4-amino-3-chloroacetophenone.  Under these conditions, 
over chlorination does not result in the addition of chlorine to the 2 and 4 positions because the 
amino and acetyl groups do not direct that addition.  Even though chlorides are ortho/para 
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directing and direct to the 2 and 4 position, chlorides are also deactivating.  With another 
option available, over chlorination would result in the product, ADAP 3P, undergoing a 
haloform-type reaction, eliminating chloroform with the addition of acetic acid to form an 
anhydride.  With a good leaving group in place, the anhydride, the reaction would proceed 
through an SNAr reaction to the 2,4,6-trichloroaniline impurity.
1,3 
The quantity, temperature, and rate of chlorine addition are critical to controlling both 
of these impurities.1   It is apparent that an under charge of chlorine would produce the mono-
chlorinated impurity, 4-amino-3-chloroacetophenone, while an over charge would produce the 
over-chlorinated impurity, 2,4,6-trichloroaniline.   
The temperature during the chlorine addition is controlled between 0 - 8°C.1  If the 
temperature goes below 0°C, then the rate of chlorination decreases causing an incomplete 
reaction, yielding the mono-chlorinated impurity, 4-amino-3-chloroacetophenone. In contrast, 
if the temperature goes above 8°C the rate of chlorination increases causing over chlorination, 
yielding the 2,4,6-trichloroaniline impurity.   
The addition rate of the chlorine is between 3 – 8 hours, typically finishing around 7 
hours.1  The concentration of chlorine in the solution is determined by the addition rate; 
therefore, slower rates produce lower concentrations and faster rates produce higher 
concentrations.  Lower concentrations of chlorine decrease the rate of chlorination and could 
result in an incomplete reaction; while higher concentrations of chlorine increase the rate of 
chlorination and could result in an over chlorination and the 2,4,6-trichloroaniline impurity.   
13 
 
 After the chlorination reaction and before the purification steps, higher amounts of the 
over chlorinated impurity, 2,4,6-trichloroaniline (30 – 50%), were observed in the lab scale 
reactions (40 g scale), versus < 0.5% in pilot plant scale reactions (12.3 kg scale, NOTE:  two 
plant batches were tested from the September 2013 campaign during an investigation of failing 
in-process control samples for drying, the process is not routinely sampled and tested for purity 
prior to the slurry in cyclohexane).  The likely reason for the difference in performance is the 
greater ability to control the amount of chlorine added and the addition rate of the chlorine gas 
on a larger scale.  The slurry in cyclohexane was effectively able to remove all of the 2,4,6-
trichloroaniline impurity formed in the lab runs.   
It should also be noted that both the lab and pilot plant runs contained < 0.5% of the 
mono-chlorinated impurity, 4-amino-3-chloroacetophenone.  Additionally, the samples tested 
from the plant after the chlorination reaction and before purification were ≥ 99.5% pure.  These 
data suggest that the purification steps could potentially be removed from the pilot plant 
process pending additional data. 
 
Bromination 
The second step of the Clenbuterol Hydrochloride 1 process (Scheme 4) is the alpha 
bromination of 4-amino-3,5-dichloroacetophenone 3P (ADAP), followed by two purification 
steps to yield 4-amino-α-bromo-3,5-dichloroacetophenone 4P (ADBAP).   
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Scheme 4:  Bromination 
 
 
Neither of the intermediates, 4 nor 4P, are tested for purity in the current manufacturing 
process at Boehringer Ingelheim Chemicals, Inc.; therefore, the purpose of the two purification 
steps and the purity of the product 4P going into the next step are not clear.  As mentioned in 
the introduction (History of the Dihydroxy Impurity), one of the ways the impurity of interest, 
4-amino-α,α-dihydroxy-3,5-dichloroacetophenone (dihydroxy impurity 7), is proposed to be 
formed is from an impurity generated during the bromination reaction, 4-amino-α,α-dibromo-
3,5-dichloroacetophenone (dibromo impurity 9, Scheme 5).  
Scheme 5:  Potential Route to the Dihydroxy Impurity from the Dibromo Impurity 
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In order to better understand the formation of dibromo impurity 9, samples were taken after 
each step during the production of the bromination process at Boehringer Ingelheim Chemicals, 
Inc. in the October 2013 pilot plant campaign, which consisted of two batches of ADBAP Crude 
4 and two batches of ADBAP Pure 4P.  The samples were analyzed for purity (area % by HPLC).   
The results are summarized in Table 2. 
Table 2: Chromatographic Purity of Bromination Steps 
Step Batch ADAP 
(3P) 
ADBAP 
(4 or 4P) 
Dibromo 
Impurity (9) 
All Other 
Impurities 
Post 
Bromination 
2034173 6.4% 75.5% 16.3% 1.8% 
2034176 4.9% 78.7% 13.8% 2.6% 
Post Slurry 2034173 1.9% 93.9% 4.2% 0.0% 
2034176 1.5% 95.5% 3.0% 0.0% 
Post 
Crystallization 
2034313 1.1% 97.9% 1.0% 0.0% 
2034315 0.5% 99.1% 0.4% 0.0% 
 One of the goals of this research is to reduce the formation of dibromo impurity 9, 
which according to the most recent campaign is formed in about 15% yield following the 
bromination reaction prior to purification.  The first step in investigating the bromination 
reaction was to determine what factors influenced the formation of dibromo impurity 9.  The 
current bromination process1 begins by heating a solution of ADAP 3P in 20 volumes of acetic 
acid (20 volumes = 20 mL per 1 g of ADAP 3P) to 62 ± 2°C.  A bromine solution in acetic acid is 
prepared and split into three equal portions.  The first portion of the bromine solution is added 
over about 15 minutes, followed by the addition of 0.2 equivalents of sodium acetate.  The 
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second portion of the bromine solution is added over about 15 minutes, followed by the 
addition of another 0.2 equivalents of sodium acetate.  The third portion of the bromine 
solution is added over about 30 minutes, and the reaction mixture is cooled to 30 ± 5°C.  A 
portion of the acetic acid is distilled, the contents are cooled, water is added, and the slurry is 
held for about an hour prior to filtration.  The product is washed with water and dried at 40 ± 
10°C under vacuum.   
Sodium acetate is added as a buffer to avoid high concentrations of hydrogen bromide, 
which will produce overbromination.1  A reaction was run in which the sodium acetate was 
added in one portion prior to the addition of the bromine solution.  These conditions resulted in 
an incomplete reaction with over 60% starting material remaining.  Based on the current 
process, the following factors were identified to potentially influence the formation of dibromo 
impurity 9:  temperature, equivalents of sodium acetate, portions of sodium acetate, rate of 
bromine addition, and concentration.   
 
First Bromination Design of Experiments (DoE) 
 The purpose of the first bromination Design of Experiments (DoE) was to determine 
which of the factors:  temperature, equivalents of sodium acetate, portions of sodium acetate, 
rate of bromine addition, and concentration, could affect the formation of 4-amino-α,α-
dibromo-3,5-dichloroacetophenone (dibromo impurity 9).  Running experiments with these five 
factors in a DoE, a full factorial design would require 32 experiments (yellow dots in Figure 5); 
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however, a quarter-factorial design was chosen, which required only 8 experiments (red arrows 
in Figure 5).   
Figure 5:  Five Factor Full-Factorial vs Quarter-Factorial 
 
The quarter-factorial design was chosen in order to scope out the design space and determine 
which factors influenced the formation of dibromo impurity 9 with the intent of later running a 
full-factor design with narrowed influencing factors.  Two center points were also added to the 
quarter-factorial design, resulting in 10 experiments.  The higher and lower limits for each of 
the five factors, which establish the design space, were based on the current process (Table 3). 
Table 3: Factors for First Bromination DoE 
Factor Current Process DoE Range 
Temperature (°C) 62 30 - 70 
Equivalents of NaOAc 0.4 0.2 – 0.6 
Portions of NaOAc 2 1 – 3 
Br2 Addition Time (hrs) 1 0.5 – 3.0 
Concentration (volumes*) 20 10 – 30 
*20 volumes = 20 mL of acetic acid per 1 g of 4-amine-3,5-dichloroacetopheone 
The predetermined output for this scoping DoE is primarily the percent of dibromo impurity 9 
based on area percent by HPLC.  However, the percent of starting material, product, and all 
other impurities were also analyzed.   
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The DoE range was entered into the statistical program, Minitab©, and the list of 
experiments was generated with a random run order.  The experiments were run on a 2 gram 
scale in the specified order.  The raw data is summarized in Table 4 and the Main Effects Plot 
for the percent of dibromo impurity 9 can be found in Figure 6.
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Table 4: Raw Data for First Bromination DoE 
Run 
Order 
Temp (°C) 
Equiv. 
NaOAc 
Portions 
NaOAc 
Br2 Addn 
Time (hrs) 
Conc. 
(Volumes*) 
% Starting 
Material 
% Product 
% Dibromo 
Impurity 
% Other 
1 70 0.2 1 0.5 10 10 81 7 2 
2 70 0.6 1 3.0 10 8 79 7 6 
3 50 0.4 2 1.75 20 13 70 17 0 
4 50 0.4 2 1.75 20 12 68 20 0 
5 30 0.6 1 0.5 30 99 1 0 0 
6 30 0.2 1 3.0 30 18 60 22 0 
7 30 0.2 3 3.0 10 19 52 29 0 
8 70 0.2 3 0.5 30 9 79 5 7 
9 70 0.6 3 3.0 30 9 76 7 8 
10 30 0.6 3 0.5 10 99 1 0 0 
*10 volumes = 10 mL of acetic acid per 1 g of 4-amine-3,5-dichloroacetopheone 
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Figure 6:  Main Effects Plot for Percent Dibromo Impurity 
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 Reviewing the slope of the lines, it was determined that concentration and portions of 
sodium acetate had a minimal effect on the formation of dibromo impurity 9 due to the nearly 
horizontal slope.  A horizontal slope indicates that experiments run at the higher and lower 
limits of that factor produced the same results for dibromo impurity 9.  On the other hand, 
temperature, equivalents of sodium acetate and bromine addition time produced steeper 
slopes indicating that these factors affect the results for dibromo impurity 9.   
Based on this data, higher temperatures, higher equivalents of sodium acetate and 
shorter bromine addition time conditions are predicted to produce lower amounts of dibromo 
impurity 9.  However, reviewing the raw data in Table 4, the experiments run with shorter 
bromine addition times at 30°C, resulted in incomplete reactions with no impurities.  This could 
potentially skew the data of the first DoE, a consequence of running a quarter-factorial design.  
However, the quarter-factorial design was chosen to determine the influencing factors, not the 
21 
 
optimum conditions for reducing dibromo impurity 9.  The defining DoEs, run with a full-
factorial design, will address the potential skewing of the data from the incomplete reactions.   
One of the benefits of DoE is the ability to show the interactions between the factors.  
The interactions between the factors that influence the dibromo impurity 9 are shown in Figure 
7. 
Figure 7:  Interaction Plot for Percent Dibromo Impurity 
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When analyzing the interaction plot, lines that cross determine if two factors have an 
interaction, with the greater interactions having a greater difference in slopes.  For example, in 
the plot on the top left for the interaction between temperature/equivalents of sodium 
acetate, at higher temperatures (the red line), the equivalents of sodium acetate does not have 
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an effect; however at lower temperatures (the black line), the equivalents of sodium acetate 
does effect the amount of dibromo impurity 9.  Based on these data, the greatest interactions 
are between temperature/equivalents of sodium acetate and temperature/bromine addition 
time.  These factors were also identified by the main effects plot to have an effect on the 
formation of dibromo impurity 9, and were further investigated in the defining DoE.   
It was noted that there were also interactions between portions of sodium 
acetate/bromine addition time and portions of sodium acetate/concentration; however, the 
interactions were smaller and the portions of sodium acetate and concentration did not have 
an effect on dibromo impurity 9 based on the main effects plot, so these factors were not 
included in future DoEs.  For future experiments, these factors were held constant, 
concentration was set at the higher concentration, lower volumes, to reduce distillation time 
during the isolation and for simplicity the portions of sodium acetate was set at one portion. 
 
Second Bromination Design of Experiments (DoE) 
 The purpose of the second bromination Design of Experiments (DoE) was to determine 
the optimum conditions for the bromination reaction by further examining the factors 
identified in the first scoping DoE to effect the formation of 4-amino-α,α-dibromo-3,5-
dichloroacetophenone (dibromo impurity 9): temperature, equivalents of sodium acetate and 
bromine addition time.  This DoE was designed as a full-factorial with center points and 
duplicates, resulting in 18 experiments.  The higher and lower limits for each of the three 
factors were based on both the current process and the first DoE (Table 5). 
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Table 5: Factors for Second Bromination DoE 
Factor Current Process 1st DoE Range 2nd DoE Range 
Temperature (°C) 62 30 – 70 50 – 70 
Equivalents of NaOAc 0.4 0.2 – 0.6 0.2 – 0.6 
Br2 Addition Time (hrs) 1 0.5 – 3.0 0.5 – 1.5 
 
This DoE focused on higher temperatures to avoid the incomplete reactions that occurred in 
the first DoE.  Additionally, the focus was moved to higher temperatures and shorter addition 
times based on the results of the first DoE.  The predetermined outputs for this DoE are the 
percent of starting material, product, dibromo impurity 9, and all other impurities based on 
area percent by HPLC.   
The DoE range was entered into the statistical program, Minitab©, and the list of 
experiments was generated with a random run order.  The experiments were ran on a 2 gram 
scale in the specified order; the raw data is summarized in Table 6 and the contour plots for 
percent of dibromo impurity 9 can be found in Figure 8. 
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Table 6: Raw Data for Second Bromination DoE 
Run 
Order 
Temp (°C) Equiv. NaOAc 
Br2 Addn 
Time (hrs) 
% Starting 
Material 
% Product 
% Dibromo 
Impurity 
% Other 
1 50 0.2 1.5 13.5 60.4 26.1 0.0 
2 50 0.2 1.5 13.3 60.0 26.7 0.0 
3 70 0.6 0.5 34.1 53.6 11.7 0.6 
4 70 0.6 1.5 10.2 77.7 11.7 0.4 
5 50 0.6 0.5 36.7 47.8 15.3 0.2 
6 50 0.6 1.5 38.4 45.2 16.3 0.1 
7 60 0.4 0.75 9.6 74.0 16.3 0.1 
8 50 0.6 1.5 36.8 47.2 15.8 0.2 
9 70 0.2 1.5 8.8 79.7 6.7 4.8 
10 70 0.2 0.5 8.3 78.4 12.4 0.9 
11 70 0.6 1.5 6.5 84.0 5.1 4.4 
12 60 0.4 0.75 9.8 76.0 13.9 0.3 
13 70 0.6 0.5 32.5 53.4 14.0 0.1 
14 50 0.2 0.5 13.8 61.0 25.2 0.0 
15 50 0.2 0.5 13.3 56.5 30.2 0.0 
16 70 0.2 0.5 8.2 78.4 11.6 1.8 
17 50 0.6 0.5 38.8 48.6 11.9 0.7 
18 70 0.2 1.5 8.4 75.7 11.0 4.9 
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Figure 8:  Contour Plots for Percent Dibromo Impurity 
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From “Contour Plot of % Dibromo vs Br2 Addn Time, Equiv NaOAc,” it was determined 
that the formation of dibromo impurity 9 is reduced with higher equivalents of sodium acetate 
at all bromine addition times, as with from “Contour Plot of % Dibromo vs Temperature, Equiv 
NaOAc”.  Therefore, it was concluded that higher equivalents of sodium acetate will minimize 
dibromo impurity 9 throughout the entire temperature and bromine addition design space.  It 
was determined from “Contour Plot of % Dibromo vs Temperature, Br2 Addn Time” that the 
formation of dibromo impurity 9 is reduced with higher temperatures and longer bromine 
addition times.  The result of longer bromine addition time conflicts directly with the result 
from the first DoE, which leads us to conclude the data from the first DoE was somewhat 
skewed due to incomplete reactions at 30°C temperatures.   
In order to find the optimum conditions, the other outputs (percent of starting material, 
product and all other impurities) were also analyzed (Figure 9).
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Figure 9:  Remaining Contour Plots for Starting Material, Product and All Other Impurities 
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In alignment with the reduction of dibromo impurity 9; reaction completion, in terms of 
reducing the percent of starting material and increasing the percent of product, also favored 
higher temperatures and longer bromine addition times.  In contrast, reaction completion 
favored lower equivalents of sodium acetate; however, with the goal of reducing dibromo 
impurity 9, using higher equivalents of sodium acetate would be a concession to sacrifice 
reaction progress for impurity reduction.  Higher equivalents of sodium acetate was also 
favored in terms of percent of all other impurities as well as dibromo impurity 9.  It is important 
to note that while dibromo impurity 9 decreases with higher temperatures and longer bromine 
additions times, the percent of all other impurities increases. 
 Based on the results of the first two DoEs, the optimum conditions for the bromination 
reaction to reduce dibromo impurity 9 are higher temperatures (70°C), higher equivalents of 
sodium acetate (0.6 equivalents), and longer bromine addition times (1.5 hours).  Since the 
optimum conditions exist at the corner of the design space, a third DoE was run keeping the 
equivalents of sodium acetate constant at 0.6 equivalents and examining higher temperatures 
and longer bromine addition times to better understand the limits of the optimum conditions. 
 
Third Bromination Design of Experiments (DoE) 
 The purpose of the third bromination Design of Experiments (DoE) was to determine the 
limits of the optimum conditions to reduce 4-amino-α,α-dibromo-3,5-dichloroacetophenone 
(dibromo impurity 9)  with respect to temperature and bromine addition time.  This DoE was 
designed as a full-factorial with center points and duplicates, resulting in 10 experiments.  The 
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higher and lower limits for each of the three factors were based on both the current process 
and the previous DoEs (Table 7). 
Table 7: Factors for Third Bromination DoE 
Factor Current 
Process 
1st DoE Range 2nd DoE Range 3rd DoE Range 
Temperature (°C) 62 30 – 70 50 – 70 70 – 90 
Br2 Addition Time (hrs) 1 0.5 – 3.0 0.5 – 1.5 1.5 – 3.0 
This DoE focused on higher temperatures and longer bromine addition times since the 
optimum conditions determined by the second bromination DoE were on the corner of the 
design space.  The predetermined outputs for this DoE are the same as with the second 
bromination DoE: the percent of starting material, product, dibromo impurity 9, and all other 
impurities based on area percent of the analytes by HPLC.   
The DoE range was entered into the statistical program, Minitab©, and the list of 
experiments was generated with a random run order.  The experiments were performed on a 
larger scale than previous DoEs, a 6 gram scale, in the specified order; the raw data is 
summarized in Table 8 and the contour plot for percent of dibromo impurity 9 can be found in 
Figure 10.
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Table 8: Raw Data for Third Bromination DoE 
Run 
Order 
Temp (°C) 
Br2 Addn 
Time (hrs) 
% Starting 
Material 
% Product 
% Dibromo 
Impurity 
% Other 
1 70 3.0 7.6 78.9 7.4 6.1 
2 70 1.5 5.9 81.9 5.2 7.0 
3 80 2.0 7.2 72.7 6.3 13.8 
4 90 3.0 8.8 60.7 6.3 24.2 
5 90 1.5 7.5 67.7 6.4 18.4 
6 80 2.0 8.6 67.4 7.2 16.8 
7 70 3.0 6.8 81.1 5.0 7.1 
8 90 1.5 8.3 64.8 6.2 20.7 
9 90 3.0 7.0 72.4 6.7 13.9 
10 70 1.5 5.2 89.3 1.9 3.6 
 
Figure 10:  Contour Plots for Percent Dibromo Impurity 
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From the contour plots of percent dibromo impurity 9 versus temperature and addition time in  
both the second and third bromination DoEs (Figure 8 and Figure 10), it was concluded that 
there is a tight range for the optimum conditions to reduce dibromo impurity 9 with a 
temperature range of 67 - 78°C and a bromine addition time range of 1.25 – 1.75 hrs. The 
contour plots for starting material, product, and all other impurities, can be found below in 
Figure 11.  
Figure 11:  Contour Plots for Starting Material, Product and All Other Impurities 
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In alignment with the reduction of dibromo impurity 9; reaction completion, in terms of 
reducing the percent of starting material and increasing the percent product, also favored 
lower temperatures (70°C) and shorter bromine addition times (1.5 hrs).  Lower temperatures 
32 
 
and shorter bromine addition times were also favored in terms of percent of all other 
impurities as well as dibromo impurity 9.   
As a result of the three bromination DoEs, the optimum conditions for the bromination 
reaction to reduce the formation of dibromo impurity 9, compared to the current process, is 
summarized in Table 9. 
Table 9: Optimum Bromination Conditions 
Factor Current 
Process 
Optimum 
Conditions 
Temperature (°C) 62 70 
Equivalents of NaOAc 0.4 0.6 
Portions of NaOAc 2 1 
Br2 Addition Time (hrs) 1 1.5 
Concentration (volumes) 20 10 
 
The optimum conditions reduced dibromo impurity 9 by 75% with comparable yields.  
Additionally, these conditions would allow for the removal of one of the purification steps, 
benefitting both time and yield.  One of the purification steps would need to remain in place to 
ensure no water is carried over into the amination/reduction reaction. 
 
Amination/Reduction 
 In the third step of the Clenbuterol Hydrochloride 1 process (Scheme 6), the bromide of 
4-amino-α-bromo-3,5-dichloroacetophenone 4P (ADBAP) is displaced by tert-butylamine 
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followed by reduction of the ketone moiety of 4P with sodium borohydride (NaBH4) to yield 
Clenbuterol Crude Free Base 5.    
Scheme 6:  Amination/Reduction 
 
 The amination/reduction reaction (4P5), is run by slowly adding ADBAP 4P to tert-
butylamine (12.5 equivalents) while keeping the temperature between 20 - 28°C.  The reaction 
mixture is held at this temperature for at least 30 minutes prior to the addition of a solution of 
sodium borohydride (3.1 equivalents assuming 4 hydrides) in water (2 volumes) while keeping 
the temperature between 20 - 28°C.  The reaction mixture is held at this temperature for at 
least 30 minutes prior to the addition of water (8 volumes).  The slurry is then held for at least 
an hour prior to filtration.  The product is washed with water and dried at 40°C under vacuum.   
 The crude product 5 is recrystallized twice in ethanol in order to remove the 4-amino-
α,α-dihydroxy-3,5-dichloroacetophenone (dihydroxy impurity 7).  Dihydroxy Impurity 7, formed 
in the amination/reduction reaction (4P5), was proposed to result from a reaction of water 
with either the starting material (4P) or dibromo impurity 9 as illustrated in Scheme 7. 
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Scheme 7:  Potential Routes to the Dihydroxy Impurity 
 
The addition of water during the amination reaction was proposed to enhance the 
formation of dihydroxy impurity 7.  A series of water spiking studies during the amination 
reaction were designed to test this hypothesis starting with both dibromo impurity 9 and 
ADBAP 4P.  Under this hypothesis, it was expected that the addition of more water would 
produce more of dihydroxy impurity 7.  The dibromo impurity 9 used in the amination water 
spiking experiments was produced with the optimum bromination conditions (See Third 
Bromination DoE Section) using 2 equivalents of bromine; the product was 95% pure by HPLC 
and was also tested for water content by Karl Fischer and found to have ≤ 0.1% water.  The 
results of the water spiking experiments with dibromo impurity 9 are summarized in Table 10. 
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Table 10: Amination Water Spiking Experiments with Dibromo Impurity  
% Water % Dihydroxy 7 % Clenbuterol 5 
% All Other 
Impurities 
0% 4.8% 85.9% 9.3% 
5% 1.8% 95.6% 2.6% 
10% 2.0% 94.1% 3.9% 
15% 1.4% 97.3% 1.3% 
 
The results of the water spiking experiments in the amination reaction with dibromo 
impurity 9 were not as expected.  Dibromo impurity 9 was not expected to form the product, 
Clenbuterol 5.  Monitoring the reaction by thin-layer chromatography (TLC) showed no reaction 
occurred when dibromo impurity 9 was added to tert-butylamine; however, once the water 
sodium borohydride solution was added, the primary product, Clenbuterol 5, was formed.  
There are two pathways in which dibromo impurity 9 could lead to Clenbuterol 5.   
In the first pathway (Scheme 8, 9155), the ketone moiety of dibromo impurity 9 is 
reduced by sodium borohydride to form the hydroxy intermediate 14, which undergoes an 
intramolecular SN2 reaction to form epoxide 15.  Tert-butylamine opens the epoxide and form 
hydroxyl imine 16 by eliminating bromide.  The imine moiety of intermediate 16 is then 
reduced by sodium borohydride to produce Clenbuterol Free Base 5.  It should also be noted 
that there are other nucleophiles in the solution (hydride and water) that could open the 
epoxide intermediate 15 to form other impurities such as trihydroxy 17 (Scheme 8, 1517).  
This may explain the larger percentage of other impurities seen in these reactions.   
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Scheme 8:  Dibromo Impurity under Amination/Reduction Conditions 
 
The second pathway (Scheme 8, 9 135) to form Clenbuterol Free Base 5 from 
dibromo impurity 9 is by reacting first with water to produce hydroxyl bromide intermediate 18 
This would be the case with the amination spiking experiments with 5 – 15% water.  It is also a 
possibility in the amination reaction with 0% water that hydroxyl bromide intermediate 18 
forms after the addition of the water sodium borohydride solution, in which dibromo impurity 9 
may react with water prior to sodium borohydride.  Hydroxyl bromo intermediate 18 collapses 
to form aldehyde 13, which then reacts with water or tert-butylamine leading to Dihydroxy 
Impurity 7 or keto-imine intermediate 19 respectively.   
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In the amination spiking experiments with 5 – 15% water, where aldehyde intermediate 
13 would be formed prior to the addition of the water sodium borohydride solution, tert-
butylamine is in larger excess, thus favoring the equilibrium toward keto-imine 19 and towards 
Clenbuterol Free Base 5 by reduction with sodium borohydride.  This explains why water 
spiking experiments with 5 – 15% water produce less dihydroxy impurity 7 than the experiment 
with 0% water.  Additionally, during the amination reaction, water acts as a catalyst in the 
formation of keto-imine 19, which explains why the 5 – 15% water spiking experiments 
produced similar amounts of dihydroxy impurity 7. 
In the amination reaction with 0% water, aldehyde intermediate 13 may be reached 
after the addition of the water sodium borohydride solution.  In this case, water would be in 
larger excess and would drive toward the formation of dihydroxy impurity 7 (Scheme 8, 137).  
dihydroxy impurity 7 is not significantly greater in the amination reaction of dibromo impurity 9 
with 0% water, because the majority would follow the first pathway (Scheme 8, 9155) due 
to the higher reactivity of sodium borohydride. 
Based on these data, dibromo impurity 9 primarily goes to form product under the 
amination/reduction conditions.  During the amination reaction, water catalyzes the formation 
of keto-imine 19, which leads to Clenbuterol Free Base 5 post reduction.  Therefore, it was 
concluded that the source of three-fold increase of dihydroxy impurity 7 was not due to the 
carry over of dibromo impurity 9 with ADBAP 4P.  In addition, the pathway to dihydroxy 
impurity 7 likely does not go through dibromo impurity 9 as originally proposed.   
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The same amination water spiking experiments were also run with ADBAP 4P to 
investigate the formation of dihydroxy impurity 7 from the reaction of water with ADBAP 4P.   
The ADBAP 4P used in these experiments was produced with the optimum bromination 
conditions as determined by the series of Design of Experiments (DoEs), and was purified as per 
the current process to ≤ 0.2% dibromo impurity 9.  The ADBAP 4P was also tested for water 
content by Karl Fischer and found to have ≤ 0.1% water.  The results of the water spiking 
experiments with ADBAP 4P are summarized in Table 11. 
Table 11: Amination Water Spiking Experiments with ADBAP  
% Water % Dihydroxy 7 % Clenbuterol 5 
% All Other 
Impurities 
0% 0.9% 98.6% 0.5% 
5% 0.8% 98.6% 0.6% 
10% 0.8% 98.4% 0.8% 
15% 1.8% 97.4% 0.8% 
 
The results of the amination water spiking experiments with ADBAP 4P were also not as 
expected; however, further insight into the mechanism of the formation of dihydroxy impurity 
7 was gained.  It was expected that without water present in the amination reaction, no 
dihydroxy impurity 7 would be formed.  Similar amounts of dihydroxy impurity 7 (about 1%) 
were formed in the experiments with 0 – 10% water, which indicates that some dihydroxy 
impurity 7 is inherent in the current process.  Dihydroxy impurity 7 was seen by monitoring 
with Thin Layer Chromatography (TLC), which additionally indicates that dihydroxy impurity 7 is 
inherent to the process and not formed on analysis by HPLC.  Based on these data, the 
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amination reaction can tolerate up to 10% water without forming any additional dihydroxy 
impurity 7.  This amount of dihydroxy impurity 7 (about 1%) aligns with the amount see in the 
original transfer of the process in 1999 as well.  The proposed pathway from ADBAP 4P to both 
dihydroxy impurity 7 and Clenbuterol Free Base 5 is shown below in Scheme 9. 
Scheme 9:  ADBAP under Amination/Reduction Conditions 
 
The pathway from ADBAP 4P to keto-amine 20 through amination followed by reduction to 
Clenbuterol Free Base 5 is the desired pathway for this reaction.  However, with tert-butyl 
amine in excess, keto-amine 20 is in equilibrium with enol 21.  Enol 21 then reacts with 
hypobromic acid, an in situ generated electrophile from a reaction of tert-butylamine 
hydrobromide salt (a byproduct of the amination reaction 4P20) and water, to form the 
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bromo amine intermediate 10, which collapses to form keto-imine 19.  Keto-imine 19 may be 
reduced to form Clenbuterol Free Base 5 or may react with water to form dihydroxy impurity 7. 
 The formation of hypobromic acid requires a certain amount of water to be present, 
likely to disassociate the hydrobromide from the tert-butylamine hydrobromide salt.  Based on 
the data in Table 11, the water needed to disassociate the hydrobromide salt is either at least 
15% water in the amination reaction or the water added with the aqueous sodium borohydride 
solution.  Again, this means that some dihydroxy impurity 7 is inherent to the process because 
there will always be water present at some point in the reaction mixture.  
 Inverse addition experiments were run by adding the solution of tert-butylamine and 
keto-amine 20 to the aqueous sodium borohydride solution.  The purpose of these experiments 
was to determine if dihydroxy impurity 7 is inherent to the process or if by increasing the 
amount of hydride relative to keto-amine 20 with the inverse addition could drive the reaction 
towards Clenbuterol Free Base 5.  The inverse addition experiments showed formation of 
dihydroxy impurity 7 throughout the addition as determined by HPLC analysis of aliquots from 
the reaction mixture.  The isolated product from the inverse addition experiments contained 
about 10% of dihydroxy impurity 7, confirming that dihydroxy impurity 7 is inherent to the 
process.  The inverse addition experiment has a greater ratio of water to tert-butylamine 
hydrobromide salt, which would facilitate the disassociation of the hydrobromide salt and thus 
explains the higher percentage of dihydroxy impurity 7 for the inverse addition.    
The three-fold increase from about 1% to about 3% of dihydroxy impurity 7 is due to  ≥ 
15% water in the amination reaction reacting with the starting material, ADBAP 4P.  The 1% of  
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dihydroxy impurity 7 present during the initial transfer of the process in 1999 to Boehringer 
Ingelheim Chemicals, Inc. is inherent to the process and formed from water added during the 
reduction step.    Reducing the presence of water in the amination reaction to ≤ 10% would 
generate only the amount of dihydroxy impurity 7 inherent to the process (about 1%), which 
could then be reduced to meet the specification for dihydroxy impurity 7 with only a single 
crystallization in ethanol.   
 
Formation of Dihydroxy Impurity in Plant Batches 
The previous section concluded that the 4-amino-α,α-dihydroxy-3,5-
dichloroacetophenone impurity (dihydroxy impurity 7) is due to the presence of ≥ 15% water in 
the amination reaction mixture reacting with 4-amino-α-bromo-3,5-dichloro-acetophenone 
(ADBAP 4P).  The amination/reduction process is currently run on a scale of about 5 kg in a 100 
L vessel.  At this scale, the 15% of water necessary to increase the formation of dihydroxy 
impurity 7 is about 60 mL.  The ADBAP 4P produced in the plant was tested for water content 
by Karl Fischer and found to have ≤ 0.1% water.  Additionally, the tert-butylamine used in the 
plant is also tested for water content by Karl Fischer to a specification of ≤ 0.5% water.11 
Therefore, the incoming materials are not the source of the ≥ 15% water in the amination 
reaction. 
The current process at Boehringer Ingelheim Chemicals, Inc. uses one vessel; therefore, 
the amination reaction of any batch other than the first batch is performed in a vessel that 
previously contained water.  Steps have been put in place to dry the reactor under heat and 
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vacuum between batches; however, based on recent batches having around 2% dihydroxy 
impurity 7, this may not be sufficient.  The configuration of the vessel could allow for hold up of 
about 60 mL without being seen.  Two efficient solutions for ensuring no water carry over from 
one batch to another are: (1) rinse with water miscible solvent such as methanol or acetone 
and dry the vessel under heat and vacuum between batches or (2) use a two vessel system in 
which no water would enter the vessel used for the amination reaction.  Additionally, the same 
pump is used to charge tert-butylamine and water in the current process.  The pump and 
associated lines could also carry over some water to the next batch.  A separate pump for tert-
butylamine should be used to eliminate the introduction of water to the amination reaction.  
With the preventative actions in place to ensure there is no carryover of water from the vessel 
or the pump used to charge tert-butylamine, the amount of dihydroxy impurity 7 should 
decrease to the amount that is inherent to the process and the amount that was seen in the 
original transfer in 1999, 1% dihydroxy impurity 7. 
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CONCLUSIONS 
 
 The chlorination process was primarily run to build starting material for an investigation 
into 4-amino-α,α-dibromo-3,5-dichloroacetophenone (dibromo impurity 9) formed in the 
bromination process.  During these experiments it was determined that the control of the 
chlorine addition in the plant greatly exceeds the control in laboratory scale additions.  With 
better control of the chlorine addition, the plant is able to control both of the main impurities 
to minimal levels that both of the chlorination purification steps could potentially be eliminated 
from the process.  This change would need additional data from plant batches tested by the 
quality control group and a quality assessment of the impact to the bromination process with 
the product of the chlorination coming out of a different solvent. 
 The bromination process was optimized through a series of Design of Experiments 
(DoEs) to reduce the formation of dibromo impurity 9.  The optimum conditions reduced the 
formation of dibromo impurity 9 by 75% from the current process while maintaining similar 
yields.   This could potentially allow for one of the bromination purification steps to be 
eliminated.  One of the purification steps would need to remain in place to ensure water is not 
carried through to the amination/reduction process.  This change would also need additional 
experiments to ensure no quality impact to the amination/reduction process. 
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 Through a series of water spiking experiments of the amination reaction with both 4-
amino-α-bromo-3,5-dichloro-acetophenone (ADBAP 4P) and dibromo impurity 9, it was 
determined that the three-fold increase in 4-amino-α,α-dihydroxy-3,5-dichloroacetophenone 
(dihydroxy impurity 7) is due to the presence of ≥ 15% water in the amination reaction reacting 
with ADBAP 4P.  The process can tolerate ≤ 10% of water in the amination reaction without 
forming additional dihydroxy impurity 7.   There is about 1% of dihydroxy impurity 7 that is 
inherent to the process and is formed from the water added in the reduction step.  The 
majority of dibromo impurity 9 carried into the process as an impurity in ADBAP 4P goes on to 
form product, Clenbuterol Free Base 5.   The current manufacturing process in the plant was 
evaluated and preventative actions to ensure there is no carryover of water from the vessel or 
the pump used to charge tert-butylamine were suggested to reduce dihydroxy impurity 7 to the 
amount (about 1%) that is inherent to the process. 
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EXPERIMENTAL DATA 
General Experimental Information 
 Commercial and reagent grade chemicals were used as obtained.  All reactions were 
conducted under nitrogen.  The 4-amino-3,5-dichloroacetophenone 3P used in the first and 
second bromination Design of Experiments was produced in the lab using the chlorination 
general procedures described below.  The 4-amino-3,5-dichloroacetophenone 3P used in the 
third bromination Design of Experiments was produced in the Bay 31 pilot plant at Boehringer 
Ingelheim Chemicals, Inc. (BICI), IA129 batch 2033835.   The chlorination procedures were 
carried out in a 1 L Lab-Max Jacketed Reactor with content temperature control.  The 
bromination and reduction/amination procedures were carried out in round-bottomed flasks 
utilizing a J-KEM connected to an oil bath for temperature control.  Temperatures of 0°C were 
obtained with ice/water bath.  Amination/Reduction reactions were monitored by thin layer 
chromatography (TLC) using Whatman MKC18F precoated silica gel plates with a 30% ethyl 
acetate in hexanes solvent system. 
Process monitoring during the chlorination and solid intermediates from the 
chlorination and bromination reactions were analyzed for purity versus analytical standards by 
high performance liquid chromatograph (HPLC) on an Agilent 1100 Series system using a Zorbax 
SD-C18 column (4.6 x 150 mm, 5 µm particle size) and gradient from 2 - 100% acetonitrile in 
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water over 30 min with a 1 mL/min flow rate.  Products from the bromination reaction were 
analyzed for water content by a Mettler Toledo Coulometric Karl-Fischer Autotitrator with 
Aquastar® Coulomat A and Aquastar® Coulomat C.  Products from the amination/reduction 
were analyzed by HPLC on an Agilent 1100 Series system using an Inertsil ODS-2 column (4.6 x 
150 mm, 5 µm particle size) and a mobile phase  5mM 1-Decane Sulfonic Acid Sodium Salt in 25 
mM Potassium Phosphate Buffer (pH 3), Methanol, Acetonitrile (69:16:15) over 70 minutes 
with a 1.5 mL/min flow rate as per intermediate specification.5  H1 NMR spectra were recorded 
on Varian Mercury-300 (300 mHz) at ambient temperature.  Chemical shifts are referenced to 
residual chloroform (δ = 7.26 ppm).   
Chlorination 
 
 
 
General Procedure for 4-Amino-3,5-dichloroacetophenone (3):  Synthesized according 
to procedure described in BICI master production record for ADAP Pure.12  A mixture of 4-
aminoacetophenone 2 (1 eq), acetic acid (9.8 vol), ethanol (1.95 vol), and water (0.5 vol) was 
cooled to 0°C.  Chlorine gas (1.8 eq) was added slowly keeping temperature between 4-10°C. 
The reaction progress was monitored by HPLC.  Water (15.25 vol) was added and the resulting 
slurry was stirred at 5°C for at least 1 hr prior to vacuum filtration and washing with water 
(18.75 vol).  The solids were dried at 40°C under vacuum overnight.  The crude product was 
then reslurried in cyclohexane (6.25 vol) by heating to 55°C for at least 30 min prior to vacuum 
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filtration and washing with cyclohexane (1.25 vol).  The solids were dried at 40°C under vacuum 
overnight to afford the titled compound.   
 
General Procedure for 4-Amino-3,5-dichloroacetophenone (3P).   Synthesized 
according to procedure described in BICI master production record for ADAP Recrystallized. 13    
A mixture of 4-amino-3,5-dichloroacetophenone 3 (1 eq) and ethanol (12.3 vol) was heated to 
reflux and slowly cooled to 0°C prior to vacuum filtration and washing with ethanol (2.9 vol).  
The solids were dried at 40°C under vacuum overnight to afford the titled compound:  H1 NMR 
(CDCl3, 300 MHz) δ 7.80 (s, 2 H), 4.91 (s, 2 H), 2.48 (s, 3 H). 
 
Bromination 
 
 
General Procedure for the Synthesis by the Current Conditions of 4-Amino-α-bromo-
3,5-dichloroacetophenone (4).  Synthesized according to procedure described in BICI master 
production record for ADBAP Crude. 14  A mixture of 4-amino-3,5-dichloroacetophenone 3P (1 
eq) in acetic acid (20 vol) was heated to 62°C.  A solution of bromine (1 eq) in acetic acid (0.6 
vol compared to bromine) was added over a specified amount of time (1 hrs) with sodium 
acetate (0.4 eq) added in 2 portions in the middle of the addition of the bromine solution.  The 
mixture was cooled to 30°C, and distilled under vacuum (50 mbar) with a temperature of 55°C 
to a minimum volume.  After cooling to 40°C, water (12.5 vol) was added and the mixture was 
48 
 
cooled to room temperature and stirred for at least 1 hr prior to vacuum filtration and washing 
with water (at least 12.5 vol).  The solids were dried under vacuum at 40°C.   The crude product 
was reslurried in ethanol (4 vol) by heating to 55°C and stirring for at least 30 min.  The mixture 
was cooled to room temperature and stirred for at least 1 hr prior to vacuum filtration and 
washing with ethanol (3 vol).   The solids were dried under vacuum at 40°C overnight to afford 
titled compound. 
 
First Bromination Design of Experiments General Procedure for 4-Amino-α-bromo-3,5-
dichloroacetophenone:  A mixture of 4-amino-3,5-dichloroacetophenone 3P (1 eq) in acetic 
acid (10 – 30 vol) was heated to 30 - 70°C.  A solution of bromine (1 eq) in acetic acid (0.6 vol 
compared to bromine) was added over a specified amount of time (0.5 – 3 hrs) with a specified 
number of portions (1 – 3) of sodium acetate (0.2 – 0.6 eq) added equally spaced throughout 
the addition of the bromine solution.  The mixture was cooled to 30°C, and distilled under 
vacuum (50 mbar) with a temperature of 55°C to a minimum volume.  After cooling to 40°C, 
water (12.5 vol) was added and the mixture was cooled to room temperature and stirred for at 
least 1 hr prior to vacuum filtration and washing with water (at least 12.5 vol).  The solids were 
dried under vacuum at 40°C overnight to afford titled compound. 
 
Second Bromination Design of Experiments General Procedure for 4-Amino-α-bromo-
3,5-dichloroacetophenone:  A mixture of 4-amino-3,5-dichloroacetophenone 3P (1 eq) in acetic 
acid (10 vol) was heated to 50 - 70°C.  A solution of bromine (1 eq) in acetic acid (0.6 vol 
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compared to bromine) was added over a specified amount of time (0.5 – 1.5 hrs) with sodium 
acetate (0.2 – 0.6 eq) added in the middle of the addition of the bromine solution.  The mixture 
was cooled to 30°C, and distilled under vacuum (50 mbar) with a temperature of 55°C to a 
minimum volume.  After cooling to 40°C, water (12.5 vol) was added and the mixture was 
cooled to room temperature and stirred for at least 1 hr prior to vacuum filtration and washing 
with water (at least 12.5 vol).  The solids were dried under vacuum at 40°C overnight to afford 
titled compound. 
Third Bromination Design of Experiments General Procedure for 4-Amino-α-bromo-
3,5-dichloroacetophenone:  A mixture of 4-amino-3,5-dichloroacetophenone 3P (1 eq) in acetic 
acid (10 vol) was heated to 70 - 90°C.  A solution of bromine (1 eq) in acetic acid (0.6 vol 
compared to bromine) was added over a specified amount of time (1.5 – 3 hrs) with sodium 
acetate (0.6 eq) added in the middle of the addition of the bromine solution.  The mixture was 
cooled to 30°C, and distilled under vacuum (50 mbar) with a temperature of 55°C to a minimum 
volume.  After cooling to 40°C, water (12.5 vol) was added and the mixture was cooled to room 
temperature and stirred for at least 1 hr prior to vacuum filtration and washing with water (at 
least 12.5 vol).  The solids were dried under vacuum at 40°C overnight to afford titled 
compound. 
 
General Procedure for the Optimized Synthesis of 4-Amino-α-bromo-3,5-
dichloroacetophenone (4):  A mixture of 4-amino-3,5-dichloroacetophenone 3P (1 eq) in acetic 
acid (10 vol) was heated to 70°C.  A solution of bromine (1 eq) in acetic acid (0.6 vol compared 
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to bromine) was added over a specified amount of time (1.5 hrs) with sodium acetate (0.6 eq) 
added in the middle of the addition of the bromine solution.  The mixture was cooled to 30°C, 
and distilled under vacuum (50 mbar) with a temperature of 55°C to a minimum volume.  After 
cooling to 40°C, water (12.5 vol) was added and the mixture was cooled to room temperature 
and stirred for at least 1 hr prior to vacuum filtration and washing with water (at least 12.5 vol).  
The solids were dried under vacuum at 40°C.   The crude product was reslurried in ethanol (4 
vol) by heating to 55°C and stirring for at least 30 min.  The mixture was cooled to room 
temperature and stirred for at least 1 hr prior to vacuum filtration and washing with ethanol (3 
vol).   The solids were dried under vacuum at 40°C overnight to afford titled compound. 
 
General Procedure for the Synthesis of 4-Amino-α-bromo-3,5-dichloroacetophenone 
4P.  Synthesized according to procedure described in BICI master production record ADBAP 
Pure. 15  A mixture of 4-amino-α-bromo-3,5-dichloroacetophenone 4 (1 eq), ethyl acetate (5.3 
vol), celite (0.04 wt%), and carbon (0.08 wt%) was heated to reflux.  The mixture was vacuum 
filtered to remove celite and carbon and washed with ethyl acetate (2.6 vol).  The resulting 
solution was heated to 45°C and vacuum distilled (50 mbar) until about 3 vols remained.  The 
mixture was cooled to 0°C and stirred for at least 2 hrs prior to vacuum filtration and washing 
with ethyl acetate (2 vol).  The solids were then dried under vacuum at 40°C overnight to afford 
titled compound:  H1 NMR (CDCl3, 300 MHz) δ 7.82 (s, 2 H), 5.05 (s, 2 H), 4.29 (s, 2 H). 
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General Procedure for the Optimized Synthesis of 4-Amino-α,α-dibromo-3,5-
dichloroacetophenone (Dibromo Impurity 9):  A mixture of 4-amino-3,5-dichloroacetophenone 
3P (1 eq) in acetic acid (10 vol) was heated to 70°C.  A solution of bromine (2 eq) in acetic acid 
(0.6 vol compared to bromine) was added over a specified amount of time (1.5 hrs) with 
sodium acetate (0.4 eq) added in the middle of the addition of the bromine solution.  The 
mixture was cooled to 30°C, and distilled under vacuum (50 mbar) with temperature of 55°C to 
a minimum volume.  After cooling to 40°C, water (12.5 vol) was added and the mixture was 
cooled to room temperature and stirred for at least 1 hr prior to vacuum filtration and washing 
with water (at least 12.5 vol).  The solids were dried under vacuum at 40°C overnight to afford 
titled compound:  H1 NMR (CDCl3, 300 MHz) δ 7.95 (s, 2 H), 6.51 (s, 1 H), 5.11 (s, 2 H). 
 
Amination/Reduction 
 
 
 
 General Procedure for the Water Spiking studies of 4-Amino-α-bromo-3,5-
dichloroacetophenone 4P in the Synthesis of Clenbuterol Free Base (5).  Synthesized according 
to procedure described in BICI master production record for Clenbuterol Crude Free Base (0 eq 
water).16  To a solution of tert-butylamine (12.5 eq) spiked with water (0 – 0.15 eq) at room 
temperature, 4-amino-α-bromo-3,5-dichloroacetophenone 4P (1 eq) was added slowly keeping 
the temperature between 20 - 28°C.  The reaction was monitored by TLC.  The mixture was 
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stirred for about 30 min.  A solution of sodium borohydride (3.1 eq assuming 4 hydrides) in 
water (2 vol) was added dropwise keeping temperature between 20 - 28°C.  The reaction was 
monitored by TLC. The mixture was stirred for about 30 min and water (8.3 vol) was added.  
The mixture was cooled to 5°C and held for at least 2 hrs prior to vacuum filtration and washing 
with water (23 vol).  The solids were then dried under vacuum at 40°C overnight to afford titled 
compound.  NMR spectrum completed on material that was twice recrystallized in ethanol:  H1 
NMR (CDCl3, 300 MHz) δ 7.18 (s, 2 H), 4.43 (dd, J = 3.3, 9.0 Hz, 1 H), 4.38 (s, 2 H), 2.83 (dd, J = 
3.6, 8.4 Hz, 1 H),  2.49 (dd, J = 3.6, 8.7 Hz, 1 H), 2.38 (s, 2 H), 1.09 (s, 9 H). 
General Procedure for Inverse Addition experiments of 4-Amino-α-bromo-3,5-
dichloroacetophenone 4P in the Synthesis of Clenbuterol Free Base (5).  To a solution of tert-
butylamine (12.5 - 25 eq) at room temperature, 4-amino-α-bromo-3,5-dichloroacetophenone 
4P (1 eq) was added slowly keeping the temperature between 20 - 28°C.  The reaction was 
monitored by TLC.  The mixture was stirred for about 30 min.  The tert-butylamine solution was 
added dropwise to a solution of sodium borohydride (3.1 eq assuming 4 hydrides) in water (2 
vol) keeping temperature between 20 - 28°C.  The mixture was stirred for about 30 min and 
water (8.3 vol) was added.  The mixture was cooled to 5°C and held for at least 2 hrs prior to 
vacuum filtration and washing with water (23 vol).  The solids were then dried under vacuum at 
40°C overnight to afford titled compound. 
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General Procedure for the Water Spiking studies of 4-Amino-α,α-dibromo-3,5-
dichloroacetophenone 9 in the Synthesis of Clenbuterol Free Base 5.  To a solution of tert-
butylamine (12.5 eq) spiked with water (0 – 0.15 eq) at RT, 4-amino-α,α-bromo-3,5-
dichloroacetophenone 9 (1 eq) was added slowly keeping the temperature between 20 - 28°C.  
The reaction was monitored by TLC.  The mixture was stirred for about 30 min.  A solution of 
sodium borohydride (3.1 eq assuming 4 hydrides) in water (2 vol) was added dropwise keeping 
temperature between 20 - 28°C.  The reaction was monitored by TLC. The mixture was stirred 
for about 30 min and water (8.3 vol) was added.  The mixture was cooled to 0°C and held for at 
least 2 hrs prior to vacuum filtration and washing with water (23 vol).  The solids were then 
dried under vacuum at 40°C overnight to afford titled compound. 
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APPENDIX A:  NMR SPECTRA 
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